A.P. Pharma Inc. (APPA) rated Buy with price target $3 by Ladenburg Thalmann
Ladenburg Thalmann rated Buy Heron Therapeutics Inc. (NASDAQ: HRTX) on 09/30/2008. Previously Ladenburg Thalmann rated Buy Heron Therapeutics Inc. (NASDAQ: HRTX) on
09/10/2008., when the stock price was $29.80. Since then, Heron Therapeutics Inc. has lost 68.32% as of 09/11/2014's recent price of $9.44. If you would have followed the previous Ladenburg Thalmann's recommendation on HRTX, you would have lost 68.32% of your investment in 2192 days.
A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company?s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.
Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann
provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann
’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.